Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical Oncology/Epidemiology
  • Published:

Clinical Oncology/Epidemiology

Prognostic value of Helix pomatia in Breast Cancer

British Journal of Cancer volume 68, pages 146–150 (1993)Cite this article

Abstract

Six hundred and eighty-four primary breast cancers from the International (Ludwig) Breast Cancer Study Group (IBCSG) were studied for Helix pomatia lectin (HPA) binding. There was a weak correlation between lymph node-positive and HPA positive (P = 0.04). In our series there was a large advantage in disease-free survival (DFS) and overall survival (OS) for node-negative patients (P < 0.0001 DFS and OS). However, there was no such advantage for HPA-negative patients (P = 0.23 DFS and P = 0.32 OS). We conclude that in this randomised patient group HPA is of no clinical predictive value.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Author information

Consortia

International (Ludwig) Breast Cancer Study Group Writing Committee: B.A. Gusterson, C.W. Taylor, K.N. Price, R.D. Gelber, J. Save-S6derbergh, R. Anbazhagan, H. Jayatilake, C.-M. Rudenstam, R. Reed, L. Morassi, P. Grigolato, M., Zorzi, R. Bettelheim, A.M. Neville, G.C. Hitchcock, M. Jagush, A. Tiltman, H.G. Schniirch, H. Bender, R. Golouh, J. Lamovec, J. Jancar, F. Martinez-Tello, K.B. Shilkin, G. Locher, K. Biirki, M. Stanisic, Th. Hardmeier, P. Luscieti, E. Passega, J. Torhorst, R.P. Baumann, E. Jacot-des-Coombes, P. Anani, A. Ng, M. Castiglione, H.-J. Senn & A. Goldhirsch. Other members of the Group are listed in the Appendix.

Rights and permissions

Reprints and permissions

About this article

Cite this article

International (Ludwig) Breast Cancer Study Group Writing Committee: B.A. Gusterson, C.W. Taylor, K.N. Price, R.D. Gelber, J. Save-S6derbergh, R. Anbazhagan, H. Jayatilake, C.-M. Rudenstam, R. Reed, L. Morassi, P. Grigolato, M., Zorzi, R. Bettelheim, A.M. Neville, G.C. Hitchcock, M. Jagush, A. Tiltman, H.G. Schniirch, H. Bender, R. Golouh, J. Lamovec, J. Jancar, F. Martinez-Tello, K.B. Shilkin, G. Locher, K. Biirki, M. Stanisic, Th. Hardmeier, P. Luscieti, E. Passega, J. Torhorst, R.P. Baumann, E. Jacot-des-Coombes, P. Anani, A. Ng, M. Castiglione, H.-J. Senn & A. Goldhirsch. Other members of the Group are listed in the Appendix.. Prognostic value of Helix pomatia in Breast Cancer. Br J Cancer 68, 146–150 (1993). https://doi.org/10.1038/bjc.1993.303

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/bjc.1993.303

This article is cited by

Search

Advanced search

Quick links